|
News
FDA approved Genentech's Avastin for treatment of Colon cancer
(Feburary, 2004). First Anti-angiogenic drug in clinic after many
years of research pioneered by Dr. Judah Folkman.
FDA approved Genentech's Lucentis (ranibizumab injection) for
treatment of wet age-related macular degeneration in June, 2006.
Avastin and Lucentis are both antibodies against VEGF.
Recent
Hot Papers
"Angiogenesis:
A Boost for Tumor Starvation" (Science 2003 301: 452-454),
an article reviews anti-angiogenic drugs in clinical development,
especially Avastin, which is expected to gain FDA approval in 2004.
Avastin and other drugs will finally prove a theory that cancer
can be treated by blocking its blood vessels, which was first proposed
by Dr. Judah Folkman forty years ago.
Lymphatic
Endothelium: A New Frontier of Metastasis Research (Nature Cell
Biology review)
|
